JPRN-jRCTs041180145
Completed
Phase 2
A Multi-Center Phase II Study in Children and Adolescence with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia - ALL-T11
Watanebe Arata0 sites364 target enrollmentMarch 29, 2019
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Watanebe Arata
- Enrollment
- 364
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The clinical trial for newly diagnosed T-ALL patients aged less than 25 years old cooperatively conducted by Japan Children's Cancer Study Group and Japan Adult Leukemia Study Group has been implemented. This trial was a BFM-based treatment with the intensification of nelarabine and L-asparaginase. It showed encouraging and comparable outcomes to other clinical trials with acceptable toxicities.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) diagnosis of T\-ALL (CD3\+ or cyCD3\+ and more than one is positive among CD2, CD5, CD7, CD8\)
- •2\) age less than 25 years old
- •3\) ECOG performance status (PS) acore of 0\-2\.However, PS scores up to 3 are permitted when the deterioration of PS is thought to be due to leukemia.
- •4\) no history of previous chemotherapy or radiation therapy
- •5\) sufficient hepatic and renal function satisfying the laboratory data listed below ;
- •(1\)T\-Bili: within 3x of age adjusted upper\-limit of normal range.
- •(2\)Creatinine: within 3x of age adjusted upper\-limit of normal range.
- •6\) written informed consent obtained from patient or guardians.
Exclusion Criteria
- •1\) Intracranial hemorrhage more than grade 3 of CTCAE v4\.0
- •2\) uncontrolled infection, including active tuberculosis and positive of HIV antibody.
- •3\) pregnancy or high possibility of pregnancy and giving suck woman.
- •4\) history of congenital or acquired immunodeficiency.
- •5\) Down syndrome.
- •6\) QTfc, corrected by Fridericia formula as QTfc \= QT/RR cube root, is more than 0\.45 seconds.
- •7\) any inappropriate status judged by physician.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Inter-groep studie voor de behandeling van kinderen en adolescenten met een B-cel non-Hodgkin lymfoom of B-ALL: Beoordeling van de werkzaamheid en veiligheid van rituximab bij patiënten met een hoog risico.childhood B-cell lymphoma childhood PMLBLB-cel non-Hodgkin lymfoom (B-NHL) bij kinderenB-cel acute lymfatische leukemie (B-ALL) bij kinderenNL-OMON21840Institut Gustave Roussy114, rue Edouard Vaillant94 805 - Villejuif France640
Withdrawn
Phase 2
Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual ImprovementBardet-Biedl SyndromeVisual ImpairmentNCT03490019University Hospital Tuebingen
Completed
Not Applicable
Phase II Clinical Study on Children and Adolescents/Young Adults with Clear Cell Sarcoma of the KidneyJPRN-UMIN000028428Japan Children's Cancer Group (JCCG)48
Unknown
Phase 2
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)Lymphoblastic Leukemia, AcuteNCT00131053Japan Adult Leukemia Study Group120
Completed
Phase 2
A Study to Explore the Effect of Sepranolone in Tourette SyndromeTourette SyndromeTourette Syndrome in AdolescenceNCT05434546Asarina Pharma26